GB777018A - Poliomyelitis vaccine products and methods for preparing the same - Google Patents
Poliomyelitis vaccine products and methods for preparing the sameInfo
- Publication number
- GB777018A GB777018A GB28404/55A GB2840455A GB777018A GB 777018 A GB777018 A GB 777018A GB 28404/55 A GB28404/55 A GB 28404/55A GB 2840455 A GB2840455 A GB 2840455A GB 777018 A GB777018 A GB 777018A
- Authority
- GB
- United Kingdom
- Prior art keywords
- vaccine
- antigen
- aluminium phosphate
- virus
- poliomyelitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960001539 poliomyelitis vaccine Drugs 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 229960005486 vaccine Drugs 0.000 abstract 5
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 3
- 229940001007 aluminium phosphate Drugs 0.000 abstract 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 3
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 201000005702 Pertussis Diseases 0.000 abstract 1
- 208000000474 Poliomyelitis Diseases 0.000 abstract 1
- 206010043376 Tetanus Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 206010013023 diphtheria Diseases 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 210000005084 renal tissue Anatomy 0.000 abstract 1
- 239000012266 salt solution Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32651—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A poliomyelitis vaccine product is prepared by absorbing the virus antigen from a killed aqueous vaccine containing at least one strain of human poliomyelitis antigen on to aluminium phosphate gel, separating the latter with the absorbed antigen and resuspending in water or a physiological salt solution. The suspension is substantially free from proteins. In preparing the starting vaccine, trypsinized macerated monkey kidney tissue is inoculated with the virus the mixture is incubated, and the living virus in the harvested fluid is inactivated with formaldehyde, ultra-violet radiation, &c. Absorption of the antigen is effected below 40 DEG C., preferably at 0-10 DEG C. The resuspension may contain 0.2-8 mg./ml. aluminium phosphate, and benzethorium chloride in concentration 1 to 10,000-50,000 as a preservative. Other antigens, e.g. tetanus, diphtheria, pertussis may also be absorbed in the aluminium phosphate. Tabulated results show that the original vaccine is less potent than the original vaccine plus aluminium phosphate and still less potent than the separated and resuspended vaccine product.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US777018XA | 1955-05-02 | 1955-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB777018A true GB777018A (en) | 1957-06-12 |
Family
ID=22139579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB28404/55A Expired GB777018A (en) | 1955-05-02 | 1955-10-05 | Poliomyelitis vaccine products and methods for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB777018A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3078215A (en) * | 1959-12-22 | 1963-02-19 | Glaxo Group Ltd | Process for the purification and concentration of poliomyelitis vaccine |
| WO2009009629A1 (en) * | 2007-07-10 | 2009-01-15 | Wyeth | Process for producing aluminum phosphate |
| US8945582B2 (en) | 2006-09-07 | 2015-02-03 | Glaxosmithkline Biologicals S.A. | Vaccine |
| JP2018518447A (en) * | 2015-06-12 | 2018-07-12 | バイオロジカル イー リミテッド | Method for producing aluminum phosphate gel for application in vaccine formulations |
-
1955
- 1955-10-05 GB GB28404/55A patent/GB777018A/en not_active Expired
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3078215A (en) * | 1959-12-22 | 1963-02-19 | Glaxo Group Ltd | Process for the purification and concentration of poliomyelitis vaccine |
| US8945582B2 (en) | 2006-09-07 | 2015-02-03 | Glaxosmithkline Biologicals S.A. | Vaccine |
| US8956625B2 (en) | 2006-09-07 | 2015-02-17 | Glaxosmithkline Biologicals, S.A. | Inactivated polio vaccines |
| WO2009009629A1 (en) * | 2007-07-10 | 2009-01-15 | Wyeth | Process for producing aluminum phosphate |
| JP2010533123A (en) * | 2007-07-10 | 2010-10-21 | ワイス・エルエルシー | Process for producing aluminum phosphate |
| RU2480403C2 (en) * | 2007-07-10 | 2013-04-27 | Вайет Ллс | Process of producing aluminium phosphate |
| CN101730660B (en) * | 2007-07-10 | 2013-06-05 | 惠氏有限责任公司 | Process for producing aluminum phosphate |
| US8540955B2 (en) | 2007-07-10 | 2013-09-24 | Wyeth Llc | Process for producing aluminum phosphate |
| AU2008275081B2 (en) * | 2007-07-10 | 2013-10-17 | Wyeth Llc | Process for producing aluminum phosphate |
| KR101387142B1 (en) * | 2007-07-10 | 2014-04-25 | 와이어쓰 엘엘씨 | Process for producing aluminum phosphate |
| EP3301074A1 (en) * | 2007-07-10 | 2018-04-04 | Wyeth LLC | Process for producing aluminum phosphate |
| JP2018518447A (en) * | 2015-06-12 | 2018-07-12 | バイオロジカル イー リミテッド | Method for producing aluminum phosphate gel for application in vaccine formulations |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES470855A1 (en) | Lyophilized native gamma globulin preparation for intravenous administration | |
| JPS6011429A (en) | Adjuvant live vaccine and manufacture | |
| ES379641A1 (en) | Ethylethyleneimine as an inactivation agent | |
| GB777018A (en) | Poliomyelitis vaccine products and methods for preparing the same | |
| US4057626A (en) | Process for detoxifying influenza B virus | |
| JPH05500803A (en) | Biological products and their use | |
| GB1108906A (en) | Antigen preparation and vaccine | |
| GB1256457A (en) | Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation | |
| GB928807A (en) | Combined poliomyelitis-diphtheria-tetanus-pertussis antigen and methods for its manufacture | |
| US3141824A (en) | Pertussis antigen | |
| GB981242A (en) | Vaccines containing rare earth salts | |
| VAHLQUIST et al. | Studies on Diphtheria: The Effect of Diphtheria Immunization of Newborn Prematures | |
| US3035980A (en) | Bacterial vaccines with p-hydroxybenzoates and their production | |
| Ananthanarayan | The fabric of virus elementary bodies | |
| Kramer et al. | Active Immunization against Poliomyelitis. A Comparative Study: IV. Experimental Immunization of Monkeys with Purified Virus, Adsorbed on Al (OH) 3 | |
| GB949400A (en) | Poliomyelitis vaccines | |
| ES266340A1 (en) | Myristyl-gamma-picolinium chloride preserved polio vaccine and its production | |
| GB770852A (en) | Vaccine products and process of producing the same | |
| GB1119543A (en) | Antigen preparation and vaccine | |
| Lycke | Studies of the accuracy of the guinea pig test for estimating antigenicity of poliomyelitis virus preparations | |
| Faulk et al. | Vaccines and vaccination programs—special emphasis in malnutrition | |
| ES8107300A1 (en) | Herpes virus vaccine and its preparation. | |
| Garcia-Sánz et al. | Comparative biological activities of whole cell pertussis vaccine and a new acellular preparation | |
| FR2143588A1 (en) | Goose hepatitis live vaccine - for active immunization of water fowl | |
| Ainbender et al. | The Difference in Elutability of Poliovirus and SV40 from a DEAE Column |